

SAWCH WILLIAM B  
Form 4  
November 02, 2004

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SAWCH WILLIAM B

2. Issuer Name and Ticker or Trading Symbol  
APPLERA CORP [ABI/CRA]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
APPLERA CORPORATION, 301 MERRITT 7  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
11/01/2004

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
Sr. V.P. and General Counsel

NORWALK, CT 06851-1070

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Applied Biosystems Group Common Stock	11/01/2004		S		275 <sup>(1)</sup>	D	\$ 19.25
							76,972.8146 <sup>(2)</sup>
Applied Biosystems Group Common Stock	11/01/2004		S		100 <sup>(1)</sup>	D	\$ 19.21
							76,872.8146 <sup>(2)</sup>
Applied Biosystems	11/01/2004		S		300 <sup>(1)</sup>	D	\$ 19.2
							76,572.8146 <sup>(2)</sup>

Edgar Filing: SAWCH WILLIAM B - Form 4

Group Common Stock							
Applied Biosystems Group Common Stock	11/01/2004	S	100 <u>(1)</u>	D	\$ 19.16	76,472.8146 <u>(2)</u>	D
Applied Biosystems Group Common Stock	11/01/2004	S	100 <u>(1)</u>	D	\$ 19.13	76,372.8146 <u>(2)</u>	D
Applied Biosystems Group Common Stock	11/01/2004	S	200 <u>(1)</u>	D	\$ 19.12	76,172.8146 <u>(2)</u>	D
Applied Biosystems Group Common Stock	11/01/2004	S	200 <u>(1)</u>	D	\$ 19.1	75,972.8146 <u>(2)</u>	D
Celera Genomics Group Common Stock	11/01/2004	S	41 <u>(1)</u>	D	\$ 13.04	17,863.0451 <u>(2)</u>	D
Celera Genomics Group Common Stock	11/01/2004	S	24 <u>(1)</u>	D	\$ 13.03	17,839.0451 <u>(2)</u>	D
Celera Genomics Group Common Stock	11/01/2004	S	17 <u>(1)</u>	D	\$ 13.02	17,822.0451 <u>(2)</u>	D
Celera Genomics Group Common Stock	11/01/2004	S	52 <u>(1)</u>	D	\$ 13.01	17,770.0451 <u>(2)</u>	D
Celera Genomics Group	11/01/2004	S	75 <u>(1)</u>	D	\$ 13	17,695.0451 <u>(2)</u>	D

Edgar Filing: SAWCH WILLIAM B - Form 4

Common Stock								
Celera Genomics Group Common Stock	11/01/2004	S	51 <sup>(1)</sup>	D	\$ 12.99	17,644.0451 <sub>(2)</sub>	D	
Celera Genomics Group Common Stock	11/01/2004	S	28 <sup>(1)</sup>	D	\$ 12.98	17,616.0451 <sub>(2)</sub>	D	
Celera Genomics Group Common Stock	11/01/2004	S	45 <sup>(1)</sup>	D	\$ 12.97	17,571.0451 <sub>(2)</sub>	D	
Celera Genomics Group Common Stock	11/01/2004	S	7 <sup>(1)</sup>	D	\$ 12.96	17,564.0451 <sub>(2)</sub>	D	
Celera Genomics Group Common Stock	11/01/2004	S	44 <sup>(1)</sup>	D	\$ 12.95	17,520.0451 <sub>(2)</sub>	D	
Celera Genomics Group Common Stock	11/01/2004	S	3 <sup>(1)</sup>	D	\$ 12.91	17,517.0451 <sub>(2)</sub>	D	
Celera Genomics Group Common Stock	11/01/2004	S	38 <sup>(1)</sup>	D	\$ 12.9	17,479.0451 <sub>(2)</sub>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: SAWCH WILLIAM B - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 6)
				Code V (A) (D)		Date Exercisable      Expiration Date	Title      Amount or Number of Shares		

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SAWCH WILLIAM B APPLERA CORPORATION 301 MERRITT 7 NORWALK, CT 06851-1070			Sr. V.P. and General Counsel	

## Signatures

Thomas P. Livingston, Attorney-in-Fact for William B. Sawch	11/02/2004
**Signature of Reporting Person	Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects transactions executed by an independent third-party administrator under the Company's Insider Diversification Program, a 10b5-1 trading plan.
- (2) Includes 588.7212 shares of Applied Biosystems Group Common Stock purchased from March to July, 2004, and 914.7332 shares of Celera Genomics Group Common Stock purchased in March and June, 2004, under the Company's employee stock purchase plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.